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Abstract
Background: Mycobacterium avium complex (MAC) is a ubiquitous pathogen, widely distributed in the
environment including water, soil and animals. It is an uncommonly encountered clinical pathogen; primarily
causing pulmonary infections in patients with underlying lung disease or disseminated disease in
immunocompromised hosts. Sporadically, extra-pulmonary infections have been documented including
involvement of the liver, spleen, skin, soft tissue and lymph nodes. Central nervous system (CNS) infections due to
MAC are exceedingly rare and carry a poor prognosis. Additionally, such infections are largely reported in patients
infected with HIV. Herein we report the first case of intracranial abscess due to MAC in an immunocompetent man
with a normal CD4 count and negative HIV status.
Case presentation: A previously healthy 40-year-old male presented to us with progressively worsening CNS
symptoms. The patient’s presentation was uncharacteristic of MAC infection in immunocompetent hosts, as he
developed subacute, progressive symptoms that included severe frontal headaches, left eyelid swelling, blurry
vision, and diplopia, without any pulmonary or systemic manifestations. Neuroimaging revealed multiple
ring-enhancing lesions, which required neurosurgical intervention. MAC was the only pathogen that grew from
intraoperative tissue cultures. The patient was subsequently treated with a 12-month regimen consisting of
Clarithromycin, Ethambutol, and Rifampin, with successful clinical resolution.
Conclusion: Our findings indicate that it is important to consider rare infections such as MAC in immunocompetent
patients, regardless of atypical symptoms. Despite the severity of this infection, with timely diagnosis effective
treatment is available.
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Background
The most prevalent nontuberculous mycobacterium
(NTM) capable of causing disease in humans is Mycobac-
terium avium complex (MAC) [1]. Organisms classified as
MAC comprise of at least two related species namely Myco-
bacterium avium and Mycobacterium avium-intracellulare.
These organisms have been recovered from water, soil,
food and milk, domestic and wild animals, though they
are readily cleared in most humans.
Infection with MAC can be acquired by ubiquitous envir-
onmental exposure. It most commonly causes pulmonary
infections in patients with chronic lung diseases, and dis-
seminated disease in the immunocompromised host [1, 2].
NTM infection, while an extremely rare cause for
CNS infection, portends a significant mortality rate, ran-
ging from 35-70 % [3]. Studies have shown that dissemi-
nated disease, previous neurosurgery, and trauma are
leading factors for CNS infection [2]. The majority of
cases involving MAC infection of the CNS are seen as
opportunistic infections in patients with acquired im-
munodeficiency syndrome (AIDS) with a severely de-
pressed CD4 count (<50 cells/μl) [4].
Here, we report the first case of brain abscess caused
by MAC in an HIV-negative male without any active
underlying immunodeficiency.
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Case presentation
A 40-year-old Caucasian male presented with a 6-week
history of chronic unremitting frontal headaches, followed
by left eyelid swelling, blurry vision, and diplopia. He sub-
sequently developed nausea and vomiting. He denied any
fever, nasal congestion, night sweats, or weight loss. His
past medical history was significant for bipolar disorder
with no other relevant findings. The patient was not using
any current medications and he denied a history of immu-
nosuppresive drugs. Moreover, his family history was only
positive for hypertension, without any mention of auto-
immune disease. On examination, the patient was afebrile,
pulse was 69 per minute, respirations were 23 per minute,
and blood pressure was 150/89 mmHg.
The physical exam was notable for exophthalmos of
the left eye as well as a palpable mass on the left eyelid.
Neurological exam revealed third, fourth, and sixth cra-
nial nerve palsy in the left eye. The patient also displayed
decreased visual acuity in the affected eye with associ-
ated early disc edema. The remainder of the physical
exam was unremarkable. The patient’s complete and dif-
ferential blood counts, serum chemistry and erythrocyte
sedimentation rate were normal. Given the findings, the
patient was referred for computed tomography (CT) to
rule out a mass lesion.
CT of the orbit with contrast revealed two frontal lobe
lesions, the largest of which appeared solid measuring
3.6 × 3.8 cm on coronal image. The lesion was seen
eroding through the orbital roof, exerting significant
mass effect on the superior rectus muscle, and causing
deformity of the left globe. An additional ring-enhancing
left frontal lesion was seen adjacent to the solid tumor
measuring 2.7 × 1.9 × 2.7 cm.
Subsequent magnetic resonance imaging (MRI) of the
brain with and without contrast revealed a mass arising
in the left orbital roof with destruction of the sphenoid
bone. Posterior to the mass was a round hyperintense
cystic area within the left inferior frontal cortex with
surrounding severe vasogenic edema. Mass effect was vi-
sualized with midline shift from left to right of the
septum pellucidum and subfalcine herniation (Fig. 1).
The contrast enhanced study showed an extensive lytic
mass measuring at least 3.4 × 2.2 cm in size. At the time,
the etiology of the lesions was felt to be more likely neo-
plastic rather than infectious in the absence of any
known immunocompromised state. Therefore, blood
cultures were not obtained.
The patient consequently underwent a left frontal crani-
otomy for partial resection of the masses. Upon incision
the large left frontal lobe lesion was full of purulent
Fig. 1 Axial T2 MRI showing a round hyperintense cystic area with surrounding vasogenic edema, and orbital involvement along with left-to-right
midline shift due to mass effect
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material from which multiple cultures were acquired. At
this point, the differential favored intracranial abscess
rather than neoplasm. Post-operative MRI noted that the
previous ring-enhancing lesions were decreased in size.
Additionally, the left retro-orbital hyperdense mass had
resolved. The prior midline displacement was improved.
Persistent vasogenic edema throughout the left frontal
lobe was noted; however, the mass effect had resolved.
Preliminary pathology from abscess resection revealed
granulomatous inflammation and necrosis with positive
acid-fast bacilli (AFB) cultures. Intraoperative bacterial,
anaerobic and fungal cultures however were all negative.
Routine blood cultures, AFB blood cultures and Quanti-
FERON® TB Gold test were also negative. The patient’s
sputum culture however was positive for AFB. Addition-
ally, the patient was tested for HIV following abscess
resection with negative results. Moreover, the patient’s
CD4 count was 515 cells/mm3 (32 %). The patient was
started on an anti-TB regimen consisting of Rifampin,
Isoniazid, Pyrazinamide, and Ethambutol.
CT of the thorax was performed to rule out a con-
comitant pulmonary infection. The study demonstrated
calcified bilateral hilar lymph nodes, as well as multiple
calcified mediastinal lymph nodes involving the prevas-
cular, pretracheal, precarinal, right paratracheal, and
subcarinal space, reflecting prior granulomatous disease
or sarcoidosis. Results from endobronchial biopsy revealed
noncaseating granulomas. Final tissue cultures from the
brain lesions and sputum revealed MAC. The patient was
started on a 12-month MAC treatment regimen con-
sisting of Clarithromycin, Ethambutol, and Rifampin. The
patient’s neurological symptoms, exopthalmous, diplopia
and mass effect fully resolved over the following 6-
months. The blurry vision persisted, but was corrected
with glasses. Sputum AFB was negative at 7-months. Fur-
thermore, follow-up MRI at 8-months was negative for
intracranial abscess.
Discussion
Mycobacterium avium complex typically affects the
lungs, but other manifestations have been described in-
cluding involvement of spleen, mesenteric lymph nodes,
liver, and intestines [5, 6, 7]. MAC infections have been
diagnosed in patients without predisposing conditions or
immunosuppression, but they typically present as focal
pulmonary or gastrointestinal diseases or occasionally in
disseminated forms usually sparing the CNS [1, 8, 9].
Disseminated disease may complicate MAC pulmonary
disease through local multiplication and entry into the
bloodstream with seeding of other organs.
The clinical presentation of MAC lung disease is non-
specific, highly variable and is influenced by whether the
patient has pre-existing pulmonary disease. The most
common clinical manifestations of disseminated MAC
include intermittent or persistent fever, night sweats,
weight loss, with additional symptoms of fatigue, malaise
and anorexia. There has been no consistent immune
deficiency identified to explain MAC infection in HIV-
negative patients. However, apparent genetic defects of
disseminated NTM infection have been associated with
specific mutations in interferon (IFN)-γ and interleukin
(IL)-12 synthesis and response pathways [10]. Addition-
ally, specific non-immunocompromised groups have
shown a predisposition for MAC pulmonary infection;
reports show an increasing prevalence of bronchiectatic
pulmonary MAC disease in elderly women without
underlying risk factors [11].
Nevertheless, CNS infection due to MAC remains rare
in patients with immunodeficiency, with even fewer case
reports published on CNS infections due to MAC in im-
munocompetent patients. In 2011, a large-scale study
was conducted to identify cases of CNS infections due
to NTM. The authors identified only 15 out of 5960
(<1 %) patients with NTM CNS infection; 11 out of
these 15 patients were HIV-seronegative. Among the pa-
tients, 1 had an infection due to Mycobacterium kansasii,
7 had infections due to Mycobacterium abscessus, and 1
presented with a mixed M. abscessus-Mycobacterium for-
tuitum infection. Only 2 cases were due to MAC (13 %)
[3]. Furthermore, an extensive search in the English lite-
rature found only 8 additional cases with MAC brain
abscess (Table 1): 7/8 patients were HIV-positive or pre-
sented with an underlying immunodeficiency [4, 9, 12–17].
Males were infected 75 % of the time and the median age
was 38 years. Additionally, the median CD4 count was
only 90 mm3 (range 2-215 mm3). The additional immu-
nocompetent case diagnosis is unclear as the patient
presented with risk factors for MAC infection. That case
described a patient with chronic granulomatous meningi-
tis who subsequently developed a secondary MAC brain
abscess as a consequence of immunosuppresion due to
prednisone therapy [12]. Moreover, the CD4 count was
unknown. Our patient however, presented with a normal
CD4 count, negative HIV status and without any existing
co-morbidities.
Diagnosis of CNS MAC may be difficult and chal-
lenging given the rarity of the condition, the potential
differential diagnosis of neoplasm as well as the vary-
ing presentations of MAC in the central nervous sys-
tem [9, 12]. Patients presenting with focal neurologic
symptoms and signs of headache, visual impairment,
ophthalmoplegia, or papilledema warrant urgent eva-
luation. MRI is superior to CT in distinguishing sus-
pected brain abscess, but culture of the specimen is
the gold standard for accurate diagnosis [9, 18]. The
specimen should be sent for Gram’s stain, aerobic, an-
aerobic, mycobacterial, and fungal cultures including
histopathology.
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Studies have failed to identify an optimal treatment
regimen in MAC CNS infections, further complicating
these cases. There is no relation between in vitro drug
susceptibility and clinical response for agents other than
the macrolides [19]. Clarithromycin is currently the only
drug for which susceptibility testing is recommended,
and is considered to be the mainstay of treatment in
combination with other agents such as Ethambutol [19].
Other chemotherapeutic options for treatment of MAC
include rifampin, rifabutin, aminoglycosides such as
amikacin, and a flouroquinolone like moxifloxacin. The
penetration of anti-NTM drugs to CNS infections is fur-
ther complicated by the relatively impermeable blood-
brain barrier (BBB). Ethambutol and the macrolides only
reach sufficient CSF concentrations in the presence of
meningeal inflammation [20]. Although rifampin shows
greater efficacy in penetrating the BBB than the other
drugs, it may be below the minimum inhibitory concen-
tration level for some microbial strains [20, 21].
Guidelines from the Centers for Disease Control and
Prevention, American Thoracic Society (ATS) and Infec-
tious Diseases Society of America (IDSA) suggest initiat-
ing treatment with at least two drugs for disseminated
MAC infection to prevent or delay the emergence of
resistance [19]. Clarithromycin is the preferred first line
agent with Ethambutol as the second recommended
drug. Some clinicians may consider adding a third drug,
either rifabutin or rifampin, in patients with dissemi-
nated MAC and HIV. Alternatively, azithromycin can be
substituted for clarithromycin as it is efficacious and
unlike clarithromycin, does not interact with rifabutin or
rifampin in patients with AIDS [19]. In HIV patients, the
United States Public Health Service and ATS/IDSA
guidelines recommend minimum therapy for 12 months
and 6 months of immune reconstitution [19]. With
MAC pulmonary disease, treatment should be continued
until sputum cultures are consecutively negative for at
least one year.
Conclusion
In summary, it is important to consider rare infections
such as MAC in immunocompetent patients, regardless
of atypical symptoms. We encourage clinicians to keep a
high index of suspicion for this condition in order to
prevent morbidity and mortality from disease progres-
sion. Furthermore, we stress the importance of obtaining
tissue cultures in order to make a conclusive diagnosis.
Combination drug therapy is essential to decrease the
risk of resistance. Additionally, treatment with more
than one agent is also associated with more rapid clear-
ance of MAC from the bloodstream. Despite the severity
of this infection, with timely diagnosis effective treat-
ment is available.
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Table 1 Summary of previous cases in the English literature
Case (Reference) Age/Sex CD4 mm3 HIV +/- Site Imaging Comorbidity
1 [4] 42/F 14 + Fronto-parietal Single, ring enhancing mass,
with mass effect
Leptomeningitis
2 [9] 52/M 175 - Occipital cerebellum Single, ring enhancing mass Tuberculosis sarcoidosis
3 [11] 38/M 90 - Frontal, parietal Multiple masses, edema Sarcoidosis
4 [12] 31/F N/A - Temporal Single mass, edema MAC meningitis, prednisone therapy
5 [13] 35/M 215 + Fronto-parietal Single mass, edema HAART, cryptococcal meningitis
6 [14] 40/M 31 + Occipital Single mass, edema HAART, CMV, retinitis
7 [15] 33/M 2 + Frontal, parietal, occipital Multiple masses, ring enhancing Disseminated MAC
8 [16] 36/M 170 + Temporal, temporo-parietal Multiple masses HAART, Disseminated MAC, PCP,
oropharyngeal candidiasis
Our case 40/M 515 - Frontal Single, ring enhancing mass,
edema and mass effect,
with invasion
-
MAC Mycobacterium avium complex, HAART Highly active antiretroviral therapy, CMV Cytolomegalovirus, PCP Pneumocystis pneumonia
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